Elekta and Royal Philips Electronics announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy.
[More]
Elekta and Royal Philips Electronics announced today that The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital has signed an agreement to join a research group to advance the development of ground-breaking image-guided treatment technology for cancer care.
[More]
Two large, landmark radiotherapy studies have shown that it is possible to treat cervical cancer effectively with high doses specifically adapted to each tumour, and with fewer serious side-effects to the surrounding normal organs.
[More]
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery - this is the finding of a new study conducted by PANAXEA, The University of Twente, Netherlands.
[More]
At the 2013 American Brachytherapy Society meeting April 18-20 in New Orleans, Nucletron, an Elekta company, (booth #300), will introduce its newly redesigned Flexitron remote afterloading platform.
[More]
The University of Texas MD Anderson Cancer Center (Houston, Texas) has purchased two Elekta Versa HD™ linear accelerators. The radiation therapy system, which recently received 510(k) clearance from the U.S. Food and Drug Administration, features the versatility to deliver high-volume conventional techniques, in addition to the most advanced linear-accelerator treatments that require the greatest targeting precision.
[More]
Elekta recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to begin shipping and installation of all components of the Versa HD™ system within the United States. Featuring high precision beam shaping and tumor targeting, and capable of delivering radiation doses three times faster than previous Elekta linear accelerators, Versa HD sets a higher benchmark for cancer treatment.
[More]
Featuring a revolutionary combination of speed and accuracy, Elekta's new Versa HD system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels.
[More]
The first-in-human study of the NeuroBlate Thermal Therapy System finds that it appears to provide a new, safe and minimally invasive procedure for treating recurrent glioblastoma, a malignant type of brain tumor.
[More]
Cancer patients referred to Hôpital Riviera's (Vevey, Switzerland) new radiotherapy clinic will soon benefit from the center's acquisition of Elekta's advanced new linear accelerator, Versa HD.
[More]
During a live global event, Elekta announced the launch of Versa HD, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers.
[More]
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.
[More]
Just over half of patients with advanced-stage esophageal cancer who are unsuitable for standard curative treatment survive for a year after receiving a combination of external beam radiotherapy and high-dose rate brachytherapy, report researchers.
[More]
IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their techniques in the successful treatment of metastatic brain cancers using IsoRay's patented Cesium-131 (Cs-131) sutured seeds.
[More]
A significant proportion of patients with prostate cancer who are treated with brachytherapy develop gross hematuria years later, report researchers.
[More]
RaySearch Laboratories AB has received an order for its RayStation® treatment planning from Consorcio Hospitalario Provincial de Castellón in Castellón, Spain.
[More]
A surgical method for treating localized prostate cancer may be a better option for patients than radiation therapy, show findings from a cost-effectiveness analysis.
[More]
The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness is reported this week by a team of researchers at the University of California, San Francisco.
[More]
A small percentage of men in a prostate cancer study complained that their penis seemed shorter following treatment, with some saying that it interfered with intimate relationships and caused them to regret the type of treatment they chose.
[More]
Elekta has received 510(k) clearance for its Clarity 4D Monitoring software, enabling U.S. medical centers to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment.
[More]